CHERRY Digital Health secures provider approval for CHERRY SmartLink – a milestone for the scalable e-prescription ecosystem
|
EQS-News: Cherry SE
/ Key word(s): Regulatory Approval
Munich, 31 March 2025 – With gematik’s provider approval for its SmartLink technology, CHERRY Digital Health has achieved a significant milestone in advancing digital healthcare. This solution facilitates the secure and user-friendly dispensing of e-prescriptions via the electronic health card (eGK) using NFC-enabled smartphones, ensuring seamless, media-continuous integration.
SmartLink represents the launch of a scalable, usage-based software model that leverages CHERRY’s existing hardware infrastructure. With over 300,000 card terminals deployed in the German healthcare sector, CHERRY establishes a seamless connection between the established telematics infrastructure (TI) hardware and new, interoperable applications. “Our development process is designed to ensure that we deliver a robust, connectable solution with real added value for all stakeholders in the healthcare sector. The provider approval marks the starting point for entering a market that is now ready for widespread adoption. Policymakers are establishing the necessary framework, and the industry is developing solutions within that framework. Now, the scaling phase begins,” says Dr. Philip Groth, Managing Director of CHERRY Digital Health GmbH. This strategic, thoughtful market entry is supported by an attractive pricing model that appeals not only to early adopters but also presents an economically compelling alternative for subsequent users, particularly within the broader pharmacy market. In an environment increasingly dominated by vertically integrated solutions, CHERRY is positioning itself as a trusted infrastructure partner, offering market neutrality and strong brand recognition. The technology will initially be implemented by DoctorBox through the new APO360 app. This application aids pharmacies in digitally engaging with their customers and integrating them into existing care pathways—ranging from the transfer of medically prescribed medication to a digital medication plan, medication reminders, and follow-up prescription requests, to the fulfillment of e-prescriptions. Additional integrations within the care sector are also planned to strengthen transmission channels between care homes and pharmacies. CHERRY SmartLink is a key component of a modular, open infrastructure stack that, alongside the TI Messenger and other applications, paves the way for digitally connected healthcare—open, interoperable, and patient-centered.
About Cherry Cherry SE [ISIN: DE000A3CRRN9] is a global manufacturer of computer input devices such as mechanical keyboards, mice, and headsets for applications in office, gaming, hygiene, and security for hybrid work, as well as hardware and software solutions in digital healthcare. Additionally, the company produces high-end mechanical switches for keyboard manufacturing. Since its founding in 1953, CHERRY has been synonymous with innovative and durable high-quality products developed specifically to meet customer needs. CHERRY’s operational headquarters is in Auerbach in der Oberpfalz (Bavaria) and it employs staff in development and production sites in Germany (Auerbach), China (Zhuhai), and Austria (Vienna), as well as in multiple sales offices in Germany (Munich, Auerbach), France (Paris), Sweden (Landskrona), the USA (Chicago), China (Shanghai), Taiwan (Taipei), and Hong Kong. For more information, visit: https://ir.cherry.de/en/
Cherry SE Nicole Schillinger Investor Relations P: Rosental 7, c/o Mindspace, 80331 Munich T: +49 (0) 9643 2061 848 E: ir@cherry.de
31.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Cherry SE |
| Rosental 7, c/o Mindspace | |
| 80331 Munich | |
| Germany | |
| ISIN: | DE000A3CRRN9 |
| WKN: | A3CRRN |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2109242 |
| End of News | EQS News Service |
|
|
2109242 31.03.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.